Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Osimertinib vs Docetaxel-Bevacizumab in EGFR T790M Mutated NSCLC
NCT02959749Phase 3Completed
- Sponsor
- Affiliated Qingdao Central Hospital of Qingdao University
- Start
- Aug 2015
- Primary completion
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of osimertinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Affiliated Qingdao Central Hospital of Qingdao University. Primary endpoint: Progression Free Survival at 10 months. Started Aug 2015; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02959749.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02959749.